Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting

MILAN, Italy, April 24, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication of an abstract submitted to The Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), to be held May 5-9 in Seattle.

“We are delighted to be presenting positive NHP safety and efficacy data from our Stargardt program demonstrating that AAV.ABCA4.intein vectors can be administered safely to NHPs under an immunosuppressive protocol designed for use in man, and at doses showing robust expression matching the pattern of endogenous ABCA4. It is encouraging to see that our AAV.ABCA4.intein product shows potential to treat retinal dystrophies, such as Stargardt Disease,” said Prof. Alberto Auricchio, CSO of AAVantgarde.

Dr. Natalia Misciattelli, CEO of AAVantgarde explained that “This positive data in NHP is very encouraging as it shows the potential of our Stargardt program, and it provides hope to the underserved Stargardt patients that currently don’t have many therapeutic options available.”

Poster Presentation details:

Presentation Number / Posterboard Number: 6097 - B0943
Abstract Title: Safety and expression following subretinal administration of AAV.ABCA4.intein vectors in the non-human primate retina
Session Number: 515
Session Title: Gene and cell therapies and other novel therapeutics II
Session Date/Time: May 9, 2024 from 8:00 AM to 9:45 AM

About AAVantgarde Bio
AAVantgarde Bio is a clinical stage, Italian headquartered, international biotechnology company that has developed two proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors. The AAVantgarde platforms could be used to deliver large genes to ocular and non-ocular tissues. Co-founded by Professor Alberto Auricchio at TIGEM (Telethon Institute of Genetics and Medicine) in Naples, Italy, and Telethon Foundation, AAVantgarde will initially validate the platform in the clinic in two inherited retinal diseases with clear unmet need. For more information, please visit:

Magda Blanco – Head of Corporate Development AAVantgarde
Phone: +44 (0) 7522 128285
Email:  [email protected]

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).